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In oncologic practice, treatment guidelines provide appropriate treatment strategies based on evidence. Currently, many guidelines 
are used, including those of the European Association for the Study of the Liver and European Organization for Research and 
Treatment of Cancer (EASL-EORTC), National Comprehensive Cancer Network (NCCN), Asia-Pacific Primary Liver Cancer Expert 
(APPLE), and Korean Liver Cancer Study Group and National Cancer Centre (KLCSG-NCC). Although radiotherapy is commonly used 
in clinical practice, some guidelines do not accept it as a standard treatment modality. In this review, we will investigate the clinical 
practice guidelines currently used, and discuss the application of radiotherapy.
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Introduction
Treatment guidelines are used in oncologic practice to provide 
the most appropriate therapeutic option(s) based on evidence. 
Currently, there are several guidelines for the treatment of 
hepatocellular carcinoma (HCC), including guidelines from the 
European Association for the Study of the Liver and European 
Organization for Research and Treatment of Cancer (EASL-
EORTC), which are based on the Barcelona Clinic Liver Cancer 
(BCLC) guidelines; the National Comprehensive Cancer Network 
(NCCN); Asia-Pacific Primary Liver Cancer Expert (APPLE); and 
the Korean Liver Cancer Study Group and National Cancer 
Centre (KLCSG-NCC). 
The application of radiotherapy (RT) has increased over 
recent decades, as has the number of studies using the latest 
technologies, such as stereotactic body radiotherapy (SBRT) 
or proton therapy (Fig. 1). Many researchers have reported 
effective clinical outcomes for patients with HCC using RT 
[1-3]. However, RT is not a recommended option in the BCLC 
guidelines or in some of the international consensuses.
This review will investigate the utilization and perspectives 
of RT in the currently used treatment guidelines, examine the 
weaknesses of the guidelines and discuss about the application 
of RT.
Evidence Grading Systems
The clinical practice guidelines for HCC adopted different 
evidence grading systems. The EASL-EORTC guidelines used two 
systems: 1) the Physician Data Query (PDQ) Levels of Evidence 
for Adult and Pediatric Cancer Treatment Studies (evidence 
classification adapted from the National Cancer Institute) 
[4] and 2) the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE) [5,6]. The GRADE 
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system, which has been adopted by many key organizations, 
was also used in the APPLE consensus guidelines and the 
KLCSG-NCC guidelines. The NCCN Guidelines used their own 
system, the NCCN categories of Evidence and Consensus. This 
system considered characteristics unique to the oncologic 
field since high-quality evidence from large randomized 
controlled trials might not always exist, and in some situations 
treatment decisions should be made based on data from non-
randomized trials or multiple retrospective studies, or even on 
the experience of physicians [7].
BCLC and EASL-EORTC Guidelines
The BCLC staging system was established by the hepatologists’ 
society, and it was first published in 1999 [8]. Numerous 
studies have been performed comparing the various HCC 
staging systems, and the BCLC staging system showed the 
best efficacy in many studies [9-11]. The BCLC staging system 
is widely used in the Asia-Pacific region; According to a report 
from the 2014 APPLE meeting, 24 of 33 institutions adopted 
the BCLC system as a staging modality [12]. In terms of 
treatment guidelines, the BCLC system has the advantage of 
recommending treatment options in accordance with stage, 
which is simple and easy to understand. 
The BCLC staging and guidelines are most commonly used 
and are strongly recommended by the American Association 
for the Study of Liver Disease (AASLD) and the EASL. The 
AASLD guidelines state that the BCLC staging is the de facto 
staging system, which is widely accepted in practice and is 
used in many clinical trials [13]. EASL and EORTC published 
comprehensive clinical practice guidelines [14] in which BCLC 
staging is the sole recommended system; the use of other 
staging systems, even in combination with the BCLC system, is 
not recommended. 
However, in the clinical guidelines of EASL-EORTC, the role 
of RT is seriously overlooked. The guidelines mention that 
the use of conventional external beam radiotherapy (EBRT) 
often causes radiation-induced liver disease (RILD) due to low 
radiation tolerance of cirrhotic liver, and the benefit of three-
dimensional conformal radiotherapy (3D-CRT) has only been 
proved in uncontrolled studies. 
RT is  ranked as the lowest for both the grade of 
recommendation and level of evidence in the guidelines. 
However, RT has been actively used in practice and its 
effectiveness has been proved in recent meta-analyses. Meng 
et al. [1] performed a meta-analysis comparing combined 
treatment of trans-arterial chemoembolization (TACE) plus RT 
Fig. 1. Graphs of number of RT for HCC publications over time. 
Citation count based on searching Scopus database, limited to 
original articles only. (A) Blue line: search for (“radiation therapy” 
OR “radiotherapy”) AND (“liver neoplasms” OR “hepatocellular 
carcinoma” OR “HCC”). (B) Blue line: search for (“SBRT” OR 
“SABR” OR “stereotactic body radiotherapy” OR “stereotactic 
ablative radiotherapy”) AND (“liver neoplasms” OR “hepatocellular 
carcinoma” OR “HCC”). Red line: search for (“proton therapy” OR 
“charged particle”) AND (“liver neoplasms” OR “hepatocellular 
carcinoma” OR “HCC”). RT, radiotherapy; HCC, hepatocellular 
carcinoma; SBRT, stereotactic body radiotherapy; SABR, 
stereotactic ablative radiotherapy; PRT, proton radiotherapy; CPT, 
charged particle therapy.
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versus TACE alone, and the combined treatment was associated 
with higher tumor response (odds ratio [OR], 3.14; 95% 
confidence interval [CI], 2.42 to 4.07) and better 2-year survival 
(OR, 2.39; 95% CI, 1.85 to 3.09). A more recent meta-analysis 
with a similar design confirmed the benefit of combined-
treatment RT in terms of 5-year survival (OR, 3.98; 95% CI, 1.89 
to 8.50) and complete tumor response (OR, 2.73; 95% CI, 1.95 
to 3.81) [15]. 
The BCLC guidelines were last revised in 2011, and do not 
reflect subsequent clinical data or practice. The pioneering 
3D-CRT studies were performed in the 1990s [16,17], and 
newly developed technologies, such as intensity-modulated 
radiation therapy (IMRT), SBRT, and charged particle therapy 
(e.g., proton therapy), which can conformally deliver doses to 
HCC safely, are now commonly practiced. In the era of these 
advanced technologies, RILD due to whole liver irradiation is an 
outdated concern. A recent meta-analysis showed the pooled 
local control rates of SBRT and charged particle therapy to 
be 87% and 86%, respectively, and the rates of acute hepatic 
toxicities of grade >3 to be 4.9% and 3.1%, respectively [3]. 
In addition, BCLC guidelines suggest single treatment 
for each stage. However, it is difficult to perform the single 
standard treatment in practice because not all medical 
facilities can provide the best treatment, and patients can 
have various conditions in one stage. In addition, combined 
treatment is commonly performed in practice, where it has 
shown favorable clinical outcomes [18-21].
EASL-EORTC guidelines look down on RT, emphasizing 
the importance of evidence from randomized clinical trials. 
However, RT has commonly been performed for patients 
with advanced disease or who failed first-line treatments 
and were not good candidates for clinical trials. Furthermore, 
the research of radiation oncology has been performed 
without major support. In addition, HCC is more prevalent in 
developing countries, such as those in Asia and sub-Saharan 
Africa [22]. In those countries, the field of medical research 
is not developed enough. Therefore, the clinical experience of 
RT should not be disregarded. In addition, the suggestion of 
combined treatment or alternative options that can be applied 
more flexibly in clinical practice should be considered.
The NCCN Guidelines
The NCCN Guidelines are one of the most comprehensive and 
widely used oncologic standards. The guidelines are presented 
in a flow-chart format, suggesting treatments according to 
clinical presentation; this is understandable and practically 
useful for physicians. The guidelines are updated at least once 
a year to ensure that they take into account the most current 
evidence [23]. 
The 2015 update of the NCCN Guidelines ver. 2.0 considers 
locoregional therapies, including ablation, arterially directed 
therapies, and EBRT as preferred treatment options for 
inoperable patients or those with unresectable disease [24]. 
In the most recent NCCN Guidelines (version 2.2016), EBRT is 
suggested as a locoregional treatment option for patients with 
unresectable HCC who are ineligible for transplantation, who 
are inoperable owing to comorbidity, or who have local disease 
with/without minimal extrahepatic disease, with evidence level 
of 2B (based on lower-level evidence, with consensus that the 
intervention is appropriate) [7]. For patients who are operable, 
locoregional therapy including EBRT is a treatment option, 
although resection is the preferred treatment [25].
The guidelines mention the feasibility of modern RT: EBRT 
allows focal high-dose irradiation to liver tumors, while 
sparing surrounding normal liver, thereby limiting the risk of 
RILD. Furthermore, EBRT can be applied irrespective of tumor 
location. The panels have considerable interests in SBRT. SBRT 
is suggested as an alternative for ablation and/or embolization 
techniques, or when they have failed or are contraindicated. 
The possible indications of SBRT are as follow: Tumors on the 
liver capsule which might be ruptured and cause track seeding 
with radiofrequency ablation (RFA) [26,27]; Lesions close to 
the major vessels where the effectiveness of ablation can be 
diminished due to the “heat sink effect” (cooling effect of 
blood flow) [28]; Lesions abutting the diaphragm which are at 
risk of diaphragmatic injury [29].
Consentient indications have not been confirmed, but SBRT 
is often performed on patients with 1–3 tumors and limited or 
no extrahepatic disease. Although SBRT is commonly applied 
for small tumors (≤4–5 cm), it may be used for larger lesions 
if sufficient uninvolved liver volume can be respected. SBRT is 
difficult to perform for lesions near the small bowel, owing to 
the risk of gastrointestinal toxicity [30]. 
The role of RT as a locoregional treatment for HCC is 
well documented in the NCCN Guidelines. Since the NCCN 
Guidelines are one of the most commonly and globally used 
oncologic guidelines, the guidelines may introduce the role of 
RT to the physicians of the oncologic society. 
The APPLE Consensus Guidelines
The APPLE is an association of liver cancer experts in the 
Asia-Pacific region, and is the most active multi-national 
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liver cancer association with International Liver Cancer 
Association (ILCA).The liver cancer specialists who participate 
in the APPLE include hepatologists, surgeons, radiologists, 
radiation oncologists, medical oncologists, and pathologists. At 
their meeting in 2014, the APPLE established comprehensive 
consensus guidelines for radiotherapy of HCC [12,31]. Specific 
recommendations for RT according to stage, based on the 
BCLC staging system, were proposed.
In the guidelines, techniques of modern EBRT, which might 
be unfamiliar for specialists other than radiation oncologists, 
are comprehensively explained. With the application of 
planning computed tomography (CT), 3D-CRT with dose-
volume histogram (DVH) analysis has enabled accurate 
research on RILD [32]. With DVH analysis, physicians can 
understand the amount of irradiated dose quantitatively. IMRT 
enables more conformal and higher dose delivery, through the 
method of inverse planning: computerized planning with given 
dose prescriptions and limitations [33,34].
SBRT (or stereotactic ablative body RT [SABR]) is described 
as the accurate delivery of ablative radiation with a relatively 
large single dose in less than 5 fractions. This treatment 
has attracted interest owing to excellent local control, short 
treatment time, and feasibility of use regardless of location. 
The number of registered prospective SBRT (or SABR) protocols 
has dramatically increased on the clinicaltrials.gov [35].
Proton therapy has an advantage in terms of dose 
distribution, with its characteristics of Bragg peak: a proton 
beam can confer a minimal dose to the front of the tumor, 
maximal dose at the tumor, and almost no dose behind the 
tumor [36]. Proton therapy showed excellent local control 
and survival in patients with HCC [37,38]. Hata et al. [39] 
performed proton therapy for 19 HCC patients with Child-
Pugh class C, who would have received supportive treatment 
according to the BCLC guidelines. Proton therapy showed 
favorable outcomes, with a 1-year overall survival rate of 53% 
and a progression-free survival rate of 47%.
Combination treatment with RT has been actively studied. 
TACE and hepatic arterial infusion chemotherapy (HAIC) have 
been used as combination agents to enhance the effect of 
RT and clinical outcomes [19,20]. Combination use of RT and 
a targeted agent, such as sorafenib, might have a synergistic 
effect, decreasing intrahepatic progression [18].
Taken together, the APPLE consensus guidelines may help 
liver specialists, not only radiation oncologists, to understand 
the applications and techniques of RT. In addition, the APPLE 
consensus guidelines were to widen application of RT for HCC 
by proposing the indications of RT across all the stages.
KLCSG-NCC Korea Guidelines
KLCSG and NCC Korea had published first practice guidelines at 
2003, and recently updated at 2014. The KLCSG-NCC aimed to 
suggest comprehensive guidelines, considering specific clinical 
conditions in Asia, which can differ from those in Western 
countries [40]. The modified Union for International Cancer 
Control (mUICC) staging system was adopted to develop the 
KLCSG-NCC guidelines.
The mUICC staging system is based on a tumor-node-
metastasis (TNM) system, which is most widely used across 
all solid tumors [41]. It helps unification of clinical data since 
the mUICC system was adopted from the first version of 
KLCSG-NCC guidelines. The BCLC staging system recommends 
treatment according to stage, and has been validated in many 
studies. It is supported by EASL and AASLD [13,14]; hence, 
it can be useful for international exchange of information. 
However, BCLC categorizes Child-Pugh class A and B patients 
into one stage, whereas the liver function of patients in 
these classes can vary widely. Moreover, the recommended 
treatments are too simple, and may not fit with clinical 
practice [40]. 
The KLCSG-NCC guidelines provide multiple treatment 
suggestions for each stage, and state the best and the 
alternative options. Proposal of multiple treatments and 
alternative options is a reasonable concept considering the 
individual circumstances of patients and the difference 
between medical facilities.
According to the guidelines, RT is an alternative option for 
mUICC stage I patients who are not candidates for resection 
or RFA. For a stage II single tumor >2 cm without vascular 
invasion, RT is also an alternative option. RT is recommended 
as one of the best options for a stage II single tumor ≤2 cm 
with vascular invasion, and a stage III single tumor >2 cm 
with vascular invasion. For stage IV patients with lymph node 
or extrahepatic metastases, RT is suggested as an alternative, 
while sorafenib is recommended as the best option. 
EBRT is usually performed for patients with Child-Pugh 
class A or favorable class B [42]. RT should be performed with 
CT-based planning, and V30 (volume irradiated ≥30 Gy) should 
be less than 60% of the liver volume. For hypofractionated 
RT with fewer than 10 fractions, the volume of normal liver 
irradiated <15 Gy should exceed 700 mL, and the mean dose 
for normal liver should be limited to <28 Gy (the dose should 
be evaluated in EQD2; equivalent dose for 2 Gy per fraction 
treatment) [32,43,44].
EBRT is recommended for incompletely treated HCC after 
RT in current clinical guidelines of HCC
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Table 1. Comparison of currently used guidelines
Guidelines Staging system Evidence stratification RT recommendation Contents of RT
EASL-EORTC BCLC GRADE [5,6]  
PDQ level of evidence [4]
– None
NCCN Child-Pugh class
UNOS criteria
NCCN Level of Evidence and  
  Consensus [7]
+/– General indications
APPLE BCLC GRADE ++ Indications according to stage
Specific RT techniques
KLSCG-NCC mUICC GRADE + Indications according to stage as 
  either one of the best or alternative 
  selections
RT, radiotherapy; EASL, European Association for the Study of the Liver; EORTC, European Organization for Research and Treatment of 
Cancer; BCLC, Barcelona Clinic Liver Cancer; GRADE, Grading of Recommendations, Assessment, Development and Evaluation; PDQ, 
Physician Data Query; NCCN, National Comprehensive Cancer Network; UNOS, United Network for Organ Sharing; APPLE, Asia-Pacific 
Primary liver Cancer Expert Meeting; KLSCG, Korean Liver Cancer Study Group; NCC, National Cancer Center; mUICC, modified Union for 
International Cancer Control.
Table 2. Clinical example of treatment applications according to practice guidelines for HCC
Guidelines BCLC NCCN APPLE KLSCG-NCCa)
Single, >2 cm, without VI Classification Early (A) Resectable or 
  transplantable
Early (A) mUICC II
Primary or 
  preferred option
LT or RFA/PEI Resection or LT LT or RFA/PEI Resection, RFA
Alternative option (–) Locoregional 
  treatment
SABR 
Hypofractionated RT
TACE, LT, EBRT
Single, ≤2 cm, with VI Classification Advanced (C) Unresectableb) Advanced mUICC II
Primary or  
  preferred option
Sorafenib Locoregional treatment 
  (ablation, arterial 
  directed therapies, 
  EBRT)
Sorafenib TACE, EBRT, 
  sorafenib
Alternative option (–) Systemic treatment
Supportive care
Combined RT Resection
Single, >2 cm, with VI Classification Advanced (C) Unresectableb) Advanced mUICC III
Primary or 
  preferred option
Sorafenib Locoregional treatment 
  (ablation, arterial 
  directed therapies, 
  EBRT)
Sorafenib TACE, EBRT,  
  sorafenib
Alternative option (–) Systemic treatment 
Supportive care
Combined RT Resection
HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer; NCCN, National Comprehensive Cancer Network; APPLE, Asia-Pacific 
Primary Liver Cancer Expert Meeting; KLSCG-NCC, Korean Liver Cancer Study Group and National Cancer Centre; mUICC, modified Union for 
International Cancer Control; LT, liver transplantation; RFA, radiofrequency ablation; PEI, percutaneous ethanol injection; VI, vascular inva-
sion; SABR, stereotactic ablative radiotherapy; RT, radiotherapy; TACE, trans-arterial chemoembolization; EBRT, external beam radiotherapy. 
a)  KLSCG-NCC guidelines are intended for patients with Child-Pugh class A, no portal hypertension, and Eastern Cooperative Oncology 
Group (ECOG) performance status 0-1. 
b) Hepatic resection for tumors with vascular invasion is controversial.
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TACE, with evidence level B2 (moderate quality of evidence 
with weak strength of recommendation) [1]. A tumor with 
portal vein invasion is also an indication, with evidence level 
C1 (low quality of evidence with strong recommendation) 
[2,20]. EBRT is an effective treatment for palliation of pain, 
which is caused by the tumor itself or bone metastases, and 
symptoms of brain, lungs, and lymph nodes metastases [45-
48]. Treatment with EBRT is expected to confer a survival 
benefit and palliation effect for patients with jaundice due 
to biliary obstruction [49]. Palliative RT is recommended with 
evidence level B1 (moderate quality of evidence with strong 
recommendation).
The KLCSG guidelines provide comprehensive information 
across various clinical fields, including diagnosis, treatment, 
surveillance, and prevention. They propose practical and 
evidence-based indications for RT in variable clinical situations, 
using an anatomically based staging system. Also, the 
guidelines provide comprehensive implementation of RT which 
is clinically helpful.
Conclusion
Comparison of the currently used guidelines is summarized 
in Table 1 [4-7]. Although RT is a frequently used treatment 
option for HCC, the applications of RT differ according to the 
guidelines. Applications of treatment, with clinical examples 
according to the guidelines, are shown in Table 2. Some 
guidelines, especially those of the EASL-EORTC, are negative 
about the application of RT, asserting the importance of 
evidence from randomized clinical trials. There are several 
ongoing randomized trials, which are expected to prove the 
efficacy of RT in the near future (Table 3). In addition, the 
clinical experiences of RT should not be neglected. RT has 
been commonly performed for patients who were hard to 
cure, and research has been performed without major support. 
We expect the globally accepted guidelines reflecting clinical 
practice, as well as adopting multimodal treatment. 
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Table 3. Phase 3 randomized clinical trials investigating role of radiotherapy in hepatocellular carcinoma
NCT no.
Estimated 
enrollment
Arms
Primary outcome 
measures
Secondary or other  
outcome measures
Estimated primary 
completion date
NCT02794337 386 Arm 1: DEB TACE 
Arm 2: DEB TACE & SBRT
In-field PFS CSS, tumor response, 
  QoL, toxicity
Jan 2019
NCT01963429 144 Arm 1: RFA 
Arm 2: Proton beam therapy
local PFS DFS, OS Dec 2018
NCT01730937 368 Arm 1: Sorafenib tosylate 
Arm 2: SBRT and sorafenib 
  tosylate
OS TTP, PFS, toxicity, QoL, 
  quality adjusted 
  survival
Jun 2016
NCT02762266 160 Arm 1: TACE 
Arm 2: SBRT
FFLP PFS, OS -
NCT02511522 60 Arm 1: Best supportive care 
Arm 2: Best supportive care 
  & RT
Improvement of 
  pain/discomfort 
Adverse event, 90-day 
  survival, QoL, reduction 
  of opioid use
Jul 2018
NCT02323360 80 Arm 1: SBRT 
Arm 2: TACE
Local control PFS, OS, toxicity Nov 2016
NCT02125396 150 Arm 1: RT 
Arm 2: TACE
OS Recurrence rate Dec 2017
DEB, drug eluting bead; TACE, trans-arterial chemoembolization; SBRT, stereotactic body radiotherapy; PFS, progression free survival; 
CSS, cause specific survival; QoL, quality of life; RFA, radiofrequency ablation; DFS, disease free survival; OS, overall survival; TTP, time to 
progression; FFLP, freedom from local progression; RT, radiotherapy.
RT in current clinical guidelines of HCC
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